{"id":"NCT01575054","sponsor":"Allergan","briefTitle":"BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-09","completion":"2015-07","firstPosted":"2012-04-11","resultsPosted":"2016-02-01","lastUpdate":"2016-09-28"},"enrollment":468,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Muscle Spasticity"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","otherNames":["BOTOX®","onabotulinumtoxin A"]},{"type":"DRUG","name":"Normal Saline","otherNames":[]}],"arms":[{"label":"botulinum toxin Type A","type":"EXPERIMENTAL"},{"label":"Normal Saline (Placebo) Followed by botulinum toxin Type A","type":"OTHER"}],"summary":"This study will evaluate the safety and efficacy of BOTOX® in the treatment of adult post-stroke lower limb spasticity.","primaryOutcome":{"measure":"Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale","timeFrame":"Baseline, 6 Weeks","effectByArm":[{"arm":"Botulinum Toxin Type A","deltaMin":4.1,"sd":0.27},{"arm":"Normal Saline (Placebo) Followed by Botulinum Toxin Type A","deltaMin":4.1,"sd":0.25}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":12,"countries":["United States","Canada","Czechia","Germany","Hungary","Poland","Russia","South Korea","United Kingdom"]},"refs":{"pmids":["29330071"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":231},"commonTop":[]}}